Last reviewed · How we verify
NCT04959760
BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test
NA trial testing The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2. in COVID-19 Respiratory Infection in 263 participants. Completed in 20 January 2022.
20 January 2022
Quick facts
| Lead sponsor | Abbott Rapid Diagnostics Jena GmbH |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 263 |
| Start date | 3 June 2021 |
| Primary completion | 20 January 2022 |
| Estimated completion | 20 January 2022 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.
Conditions studied
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
Sponsor
Abbott Rapid Diagnostics Jena GmbH
Who can join
18 and older, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Performance evaluation of the BinaxNOW™ COVID-19 IgG Rapid Test Device (Professional Use) and with BinaxNOW™ COVID-19 Antibody Self Test wehn used with fingerstick capillary whole blood and plasma samples. The BinaxNOW™ Antibody Tests are lateral flow tests that measure SARS-CoV-2 IgG antibodies.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Evaluation of the Panbio™ COVID-19 IgG rapid test device performance.
Moy JN, Amin AM, Chalmers-Watson C, Chowdhury R, et al · · 2023 · PMID 38125420 · DOI 10.1016/j.heliyon.2023.e22612 -
Evaluation of the Panbio™ COVID-19 IgG Rapid Test Device Performance
Moy JN, Amin AM, Chalmers-Watson C, Chowdhury R, et al · · 2023 · DOI 10.2139/ssrn.4441401
Verify or expand the search:
- PubMed search for NCT04959760
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Respiratory Infection
Currently open trials in the same condition.
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
- NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting
Other Abbott Rapid Diagnostics Jena GmbH trials
Trials by the same sponsor.
- NCT05163730 — Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04959760 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abbott Rapid Diagnostics Jena GmbH
- Last refreshed: 9 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04959760.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing